Oppenheimer Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) but lowers the price target from $36 to $31.

May 09, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer maintains an Outperform rating on Viridian Therapeutics but lowers the price target from $36 to $31.
The adjustment in price target by a prominent analyst like Leland Gershell, while maintaining an Outperform rating, suggests a positive outlook on VRDN's fundamentals but with a more conservative valuation. This could lead to mixed short-term market reactions, as investors recalibrate their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100